• Spermine: From Ion Channel Probe to Translational Strategy

  2026-08-14

  Spermine is more than a metabolic polyamine: it is a mechanistically informative regulator of inward rectifier potassium channels and a practical probe for connecting ion channel regulation with cell growth, protein synthesis, and cellular metabolism research. This thought-leadership article outlines how translational teams can deploy Spermine rigorously, while assessing what the discovery of CLCC1 in herpesvirus nuclear egress does—and does not—justify for membrane biology and antiviral research.

• HyperScript RT SuperMix for qPCR: NAFLD Assay Design

  2026-08-14

  Discover how HyperScript RT SuperMix for qPCR can support rigorous cDNA synthesis for qPCR in NAFLD research. This assay-design guide translates a network pharmacology and HepG2 validation study into practical decisions for transcript selection, reverse transcription, controls, and interpretation.

• AP20187 Workflows for Conditional Signaling

  2026-08-13

  AP20187 enables ligand-controlled fusion protein dimerization for reporter assays, engineered receptor activation, and regulated cell therapy research. This practical guide connects compound handling with construct validation, quantitative readouts, and troubleshooting while clearly separating established product performance from workflow recommendations.

• COX-2 Pathway in Venom-Induced Muscle Injury

  2026-08-13

  A January 2025 Microvascular Research study shows that COX-2 has a time-dependent role after Bothrops asper venom injury: its early activity helps preserve vascular integrity, whereas early inhibition later enhances angiogenic and matrix-remodeling signals. The findings provide a mechanistic framework for interpreting selective COX-2 inhibition in muscle ischemia and revascularization models.

• Calpain Inhibitor II, ALLM: Assay Guide

  2026-08-12

  A scenario-driven guide to using Calpain Inhibitor II, ALLM (SKU A2603) in viability, apoptosis, and protease inhibition workflows. It connects defined protease affinities and formulation data with practical controls for leukemia, lymphoma, and FAK-proteolysis studies.

• Stattic and the Translational Logic of STAT3 Inhibition

  2026-08-12

  STAT3 is more than a tumor-cell survival pathway: it is a convergence point for inflammatory, metabolic, and microenvironmental signals. This thought-leadership article examines how Stattic can help translational researchers connect mechanistic STAT3 perturbation with cancer biology, radiosensitization, and microbiome-linked signaling while preserving appropriate experimental boundaries.

• Fluorouracil and Tumor Evolution in CRC Assays

  2026-08-11

  Fluorouracil research is often reduced to a single potency value, but tumor evolution can make that interpretation misleading. This guide connects 5-Fluorouracil mechanism, assay design, and colorectal cancer heterogeneity for more informative preclinical studies.

• Talabostat Mesylate: DPP4/FAP Assay Logic

  2026-08-11

  Talabostat mesylate and PT-100 are examined through a mechanistic lens that separates DPP4/FAP biology from DPP8/9–NLRP1 inflammasome signaling. This guide translates that distinction into better cancer, immune, and cross-domain assay decisions.

• CX-5461 Drives Mitotic Catastrophe in Cervical Cancer

  2026-08-10

  The reference study identifies a mechanistic link between Pol I inhibition, DNA damage, aberrant mitotic entry, and cervical cancer cell death or senescence. It further shows that CX-5461 can increase cisplatin sensitivity, supporting investigation of RNA polymerase I inhibition in primary or platinum-resistant cervical cancer models.

• Talabostat mesylate: Practical Cancer Assay Workflows

  2026-08-09

  Talabostat mesylate (PT-100) supports controlled studies of DPP4 and FAP in tumor, stromal, and immune-cell models. This guide connects FAP-focused cancer workflows with a carefully bounded inflammasome application inspired by recent vaccinia virus research, while emphasizing controls, selectivity, and troubleshooting.

• BIBP 3226 Trifluoroacetate for Arrhythmia

  2026-08-08

  Use BIBP 3226 trifluoroacetate to separate NPY Y1-driven electrical phenotypes from broader neuropeptide signaling in coculture, cAMP, and receptor assays. Its affinity profile and fresh-solution workflow make it a practical probe for cardiovascular regulation research, with extensions to anxiety and analgesia mechanism studies.

• Thiazovivin: Practical ROCK Inhibitor Guide

  2026-08-07

  Thiazovivin is a research-use ROCK inhibitor for workflows involving fibroblast reprogramming, induced pluripotent stem cell generation, and recovery of human embryonic stem cells after dissociation. This guide covers preparation, controls, handling, and interpretation when direct matched paper evidence is unavailable; it is not a diagnostic, therapeutic, or clinical-use protocol.

• Moxidectin Boosts Polyene Efficacy Against Candida via Ergos

  2026-08-07

  This study demonstrates that moxidectin enhances the antifungal efficacy of polyene antibiotics, such as amphotericin B, by elevating ergosterol biosynthesis in Candida albicans. The findings suggest a promising strategy to improve fungal infection therapies and tackle antifungal resistance.

• Praeruptorin A: Advanced Insights for Ulcerative Colitis Mod

  2026-08-06

  Explore Praeruptorin A, a unique angular pyranocoumarin compound, as an innovative anti-inflammatory agent for ulcerative colitis research. This article reveals new mechanistic insights, practical protocol guidance, and differentiation from existing inflammation and ferroptosis studies.

• Cisplatin in Translational Oncology: Mechanisms and Strategi

  2026-08-06

  Explore how mechanistic insights into Cisplatin (CDDP) inform next-generation translational oncology, focusing on the interplay between DNA damage, apoptosis, and emerging resistance mechanisms. Drawing on recent findings about ZNF263/STAT3-driven chemoresistance, and integrating protocol benchmarks, this article delivers actionable guidance for researchers seeking to optimize cancer models, overcome therapeutic resistance, and bridge preclinical discoveries to clinical impact. APExBIO's Cisplatin (SKU A8321) is central to these advances, providing reliability and mechanistic clarity across cancer research workflows.

16399 records 1/1094 page Next 12345 下5页 Last page